Screener
BioMarin Pharmaceuticals BMRN Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Long-term investments | — | 492,242 |
| Property, plant and equipment, net | 989,994 | 952,508 |
| Intangible assets, net | 4,879,367 | 213,837 |
| Goodwill | 655,745 | 196,199 |
| Deferred tax assets | 888,575 | 1,508,697 |
| Other assets | 338,138 | 277,049 |
| Total assets | $11,723,442 | $7,594,022 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's goodwill?
- BioMarin Pharmaceuticals (BMRN) reported goodwill of $655.75M in Q2 2026.
- How has BioMarin Pharmaceuticals's goodwill changed year-over-year?
- BioMarin Pharmaceuticals's goodwill increased by 234.2% year-over-year, from $196.2M to $655.75M.
- What is the long-term trend for BioMarin Pharmaceuticals's goodwill?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $196.2M to $196.2M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about BioMarin Pharmaceuticals's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude